Trial Information
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Inclusion Criteria
Inclusion Criteria
- Prostate cancer
- Radical prostatectomy or external beam irradiation therapy within 6 months before
study entry.
- No bone metastases according to bone scan
Exclusion Criteria
- Metastatic prostate cancer
- Hormone ablation therapy for more than 3 months before/after radical prostatectomy
and external beam irradiation therapy
- Treatment with bisphosphonates or other drugs known to affect the skeleton within the
past year.
Other protocol-defined inclusion / exclusion criteria may apply.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To assess the activity of one year treatment with zoledronic acid
Principal Investigator
Novartis Pharmaceuticals
Investigator Role:
Study Director
Investigator Affiliation:
Novartis Pharmaceuticals
Authority:
Greece: National Organization of Medicines
Study ID:
CZOL446GGR01
NCT ID:
NCT00219271
Start Date:
September 2003
Completion Date:
September 2009
Related Keywords:
- Prostate Cancer
- Prostate cancer
- molecular staging
- antitumor potential
- Prostatic Neoplasms